Dx & Vx

Dx & Vx is a bio-healthcare company based in South Korea, established in 2001 and previously known as CancerLab Co., Ltd.

The company focuses on medical diagnostics, drug development, consumer healthcare, and digital healthcare. In 2022, it rebranded to its current name. The company offers a range of services, including molecular genetic testing, diagnostic services, and health check services. Its product and research portfolio features microbiome-based consumer health supplements, personal care products, and various drugs targeting respiratory diseases, macular degeneration, atopy dermatitis, xerophthalmia, and cancer. Dx & Vx is also involved in developing next-generation therapeutic platforms and has a pipeline addressing infectious diseases, cancer, obesity, and eye diseases. Dx & Vx has engaged in significant collaborations, partnering with over 40 global pharmaceutical and biotechnology companies. Notably, it has a co-development and license agreement for an mRNA cancer vaccine valued at approximately USD 220 million.